The study exploited a deceptively simple but powerful model system, the budding yeast Saccharomyces cerevisiae. The researchers worked with 354 inbred yeast strains originally developed in a previous effort, a cohort that collectively carries roughly 12,000 single-nucleotide polymorphisms distributed across all yeast chromosomes and even the mitochondrial genome. Because the strains are inbred, their alleles segregate in an approximately 50:50 pattern, which gives the mapping approach clean statistical footing. Crucially, this kind of population has long been a workhorse for classical quantitative trait loci studies, but the Montreal team asked a question that had rarely been posed at this scale: rather than measuring visible traits or mRNA levels, could they measure the strength of protein–protein interactions themselves as quantitative traits, and then trace those measurements back to specific DNA variants?

To answer that question, the group deployed a protein-fragment complementation assay built on murine dihydrofolate reductase, or DHFR. The strategy works like a molecular switch. Each of two interacting partner proteins is fused to a complementary fragment of the DHFR enzyme. When the two proteins come together in the living cell, the fragments reconstitute a functional enzyme that confers resistance to the drug methotrexate. Growth under drug pressure therefore becomes a quantitative, high-throughput readout of interaction strength: the more strongly two proteins associate, the better the cells survive. The researchers engineered 61 such reporter pairs, tagging the relevant genes directly in the chromosomes of every strain using a streamlined CRISPR/Cas9 and homologous recombination workflow, and gave each strain a unique DNA barcode so that all 354 genomes could be pooled and sequenced together in a single competitive growth assay.

The results, presented across a series of Manhattan plots and quantitative maps, revealed a rich landscape the authors call the genetic architecture of protein–protein interactions, summarized in a new class of loci they named piQTLs, protein-interaction quantitative trait loci. Across 61 reporter pairs and five growth conditions, the team identified roughly 1,180 lead variants, about four per reporter pair per condition, corresponding to 354 unique SNPs spread over 282 distinct gene loci. The single most striking pattern concerned the split between cis- and trans-acting effects. Variants acting in cis, meaning they sit near the genes encoding the interacting pair itself, were rare. Variants acting in trans, located anywhere else in the genome and often on entirely different chromosomes, dominated the landscape and carried noticeably stronger per-variant effect sizes. In this respect, the regulation of protein interactions echoes a theme well established for gene expression, where trans effects are numerous and diffuse, but the interaction layer adds its own architectural twist.

That twist emerged when the researchers looked at where trans-piQTLs fall in the yeast protein interaction network. Consistent with the small-world architecture that characterizes protein networks, variants influencing a given reporter interaction tended to map to genes encoding proteins that sit close to that reporter pair in the network, even when the variants were far away in genomic space. The team formalized this observation through large-scale simulations, randomly drawing comparable sets of genes 10,000 times and asking how often they would fall as near to a reporter pair as the real piQTLs did. The answer was clear: the observed proximity was not a product of chance. This network-proximity principle is more than a statistical curiosity. It suggests that the web of interactions inside a cell channels the downstream effects of genetic variation, meaning that perturbations propagate along local neighborhoods of the interactome rather than scattering randomly, a property that could be exploited to prioritize candidate causal genes in human disease studies.

Perhaps the most provocative findings came from the poorly annotated corners of the yeast genome. The researchers identified and experimentally validated piQTLs in noncoding RNAs, including the Xrn1-sensitive antisense transcripts known as XUTs, as well as in 3′ untranslated regions, and these regulatory variants carried effect sizes comparable to those of variants landing squarely inside protein-coding sequences. In other words, DNA that does not code for protein can still measurably tune how two proteins grip each other in vivo. This finding expands the functional repertoire of noncoding variation and hints that some of the so-called missing heritability of complex human traits, the gap between known genetic associations and explained disease risk, may hide not only in unannotated regulatory DNA but in its consequences for the physical wiring of the proteome.

The study also delivered an instructive comparison with two other molecular QTL disciplines, expression QTLs that track mRNA abundance and protein abundance QTLs that track protein levels. When the team overlapped their piQTLs with results from highly powered yeast linkage studies, including an eQTL analysis of 942 diverse isolates and a pQTL analysis of 1,086 near telomere-to-telomere genomes, a telling asymmetry appeared: piQTLs overlapped more with pQTLs than with eQTLs, even after rigorous size-matched permutation testing. The interpretation is that protein interactions sit downstream of transcription and closer to the proteome-level machinery of the cell, capturing post-transcriptional regulation, protein abundance effects and molecular assembly processes that RNA measurements simply cannot see. Some variants alter how much of a protein is made; others change what that protein does once made, and the interactome assay registers both.

The practical payoff of the approach became visible when the researchers grew their pooled strains under drug treatment. In experiments with methotrexate, fluconazole, 5-fluorocytosine, metformin and trifluoperazine, drug-specific piQTLs emerged that traced the mechanism of action of each compound through the interaction network. Fluconazole, an antifungal that targets the Erg11 enzyme of the ergosterol pathway, produced piQTLs concentrated in genes linked to that pathway, including variants inside the Erg11 coding sequence itself. Metformin, the widely used diabetes drug, revealed interaction changes in mitochondrial and metabolic proteins that align with known aspects of its biology. This capacity to read a drug’s fingerprint directly off the interactome suggests that piQTL mapping could become a genuine screening tool, one that identifies variants modulating drug response and flags off-target mechanisms that conventional growth assays might miss entirely.

All of the raw sequencing data, computational code and mapping results have been released openly, with raw reads deposited in the Gene Expression Omnibus, analysis pipelines on GitHub, and an interactive web server that lets any visitor browse the Manhattan plots, quantile–quantile diagnostics and a genome browser annotated with noncoding RNA features. The authors acknowledge clear limitations, including the modest number of reporter interactions surveyed relative to the thousands of interactions known in yeast and the statistical power constraints of a 354-strain cohort, which can only detect effect sizes of roughly 0.06 or larger. Yet the conceptual advance is hard to overstate. By demonstrating that the strength of protein–protein interactions behaves as an ordinary quantitative trait that can be mapped across a genome, the study opens a third major molecular dimension for genetics, beyond transcript and protein abundance, and points toward a future in which the interpretive power of human genome-wide association studies is amplified by the connective tissue of the cell, the interaction networks where biology actually happens.

Subject of Research: Mapping how natural genetic variation alters in vivo protein–protein interaction strength in budding yeast.

Article Title: Genetic landscape of an in vivo protein interactome

Article References: Genetic landscape of an in vivo protein interactome. (n.d.). https://doi.org/10.1038/s41588-026-02747-z

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02747-z

Keywords: protein–protein interactions, piQTL, yeast genetics, quantitative trait loci, noncoding RNAs, GWAS, missing heritability, proteome, CRISPR, drug mechanisms, interaction networks, functional genomics

The researchers set out to close a major gap in kinome pharmacology. Protein kinases—the 518 enzymes that phosphorylate most human proteins and orchestrate nearly every cellular process—are not merely catalytic cores. Beyond their conserved kinase domains, they carry additional domains that mediate autoinhibition, subcellular localization, and complex formation. Autoinhibitory domains (AIDs) typically keep kinases dormant by docking onto the kinase domain and masking the ATP-binding site, blocking both enzymatic activity and substrate interactions until an activating signal relieves this restraint. Classical structural methods struggle to characterize these domains because many AIDs are intrinsically disordered or connected to the catalytic core through flexible linkers, and most structural studies rely on truncated, purified recombinant proteins that lack the physiological post-translational modifications and binding partners essential for correct function. Whether ATP-competitive inhibitors, which stabilize the active DFG-in conformation of the kinase domain, also force structural changes at the AID remained a poorly explored dark space.

To address this, the team developed a multimodal proteomics strategy combining three complementary mass spectrometry-based approaches. The first, AP-LiP-MS, applies limited proteolysis coupled to mass spectrometry on affinity-purified samples: kinases are purified from human cells under native conditions, treated with an inhibitor, and then exposed to proteinase K, which preferentially cleaves accessible and flexible regions. Changes in the resulting conformation-specific peptide fragments reveal structural shifts with high sequence coverage while preserving the native cellular context. This structural readout was paired with contextual proteomics—affinity purification mass spectrometry (AP-MS) to measure complex formation and in vivo proximity labeling using the miniTurbo biotin ligase to map the kinase’s biochemical neighborhood in living cells. The approach was first benchmarked on the kinase DCLK1, where known X-ray crystal structures of the autoinhibited and inhibitor-bound states confirmed that AP-LiP-MS faithfully detects the anticipated structural rearrangements.

Applying the workflow to three disease-associated kinases with well-characterized ATP-competitive inhibitors—CAMKK2 targeted by SGC-CAMKK2-1, CHEK1 targeted by rabusertib, and PRKCA targeted by Gö 6983—the researchers found a striking common theme. In every case, inhibitor binding produced structural changes precisely at the autoinhibitory domain, with increased proteinase K susceptibility indicating that the AID becomes more solvent-exposed. This is consistent with the AID dissociating from the kinase domain, driving the inhibited enzyme into an open, active-like conformation that mimics the structural unlocking that occurs during normal kinase activation. Notably, a structurally similar negative control compound that does not bind CAMKK2 induced neither structural nor interaction changes, confirming the specificity of the observations. For PRKCA, structural alterations extended into the membrane-binding C2 domain, specifically at a short regulatory segment associated with autoinhibition, hinting that multiple domain-domain interactions are disrupted by drug binding.

The consequences of these conformational shifts proved to be as diverse as they were unexpected. For CAMKK2, the inhibitor stabilized a complex between CAMKK2 and PRKAA1, the catalytic subunit of the AMPK energy-sensing complex. Catalytically inactive and autonomously active CAMKK2 mutants responded to the drug with the same interaction pattern, demonstrating that the effect depends on the conformational change rather than on catalytic inhibition. Structural modeling with AlphaFold3 suggested that the activation-relevant T183 residue of PRKAA1 becomes buried within the predicted CAMKK2–PRKAA1 interface. Functional experiments confirmed the implication: in glucose-starved cells, SGC-CAMKK2-1 reduced T183 phosphorylation of PRKAA1 by upstream kinases such as LKB1, and this suppression was rescued when CAMKK2 was depleted by siRNA. In other words, the inhibited kinase acts as a physical shield that sequesters AMPK and blocks its activation through an entirely non-catalytic, scaffolding mechanism—potentially shutting down both the calcium-dependent and energy-stress branches of AMPK signaling simultaneously.

Strikingly, a disease-associated CAMKK2 variant, the R311C mutation found in a patient with bipolar disorder, completely abolished the inhibitor-induced interaction with PRKAA1. Because R311 faces the predicted interaction interface while the neighboring catalytic residue D312 lies outside it, the finding offers the first mechanistic clue for how this genetic variant may uncouple the CAMKK2–AMPK signaling axis in patients, and it underscores that drug responses can depend critically on the specific disease variant a patient carries—a consideration for personalized medicine.

The second model kinase, CHEK1, revealed a different flavor of paradox. Rabusertib remodeled CHEK1’s interactions with numerous DNA-damage response proteins, increasing binding to 14-3-3 proteins, the deubiquitylating enzyme USP7, PCNA, and MCM replication licensing factors, and elevating phosphorylation at the ATR-targeted S317 site—changes mirroring those seen during genuine DNA damage-induced activation. The single interactor that dissociated was CLPB, a mitochondrial protein previously identified in multiple studies as a CHEK1 partner. CLPB dissociation occurred in both wild-type and catalytically inactive CHEK1 but not in a constitutively open mutant, again implicating the conformational rather than catalytic consequence of inhibition. Because CLPB loss is known to cause mitochondrial fragmentation, the researchers examined mitochondrial morphology by super-resolution microscopy. Rabusertib treatment significantly increased mitochondrial fragmentation, an effect that persisted even when the canonical CDK1–DRP1 fragmentation pathway was blocked with the CDK1 inhibitor RO-3306, and that could not be reproduced by DNA damage alone. While a direct causal link between CHEK1–CLPB dissociation and fragmentation remains to be established, the data suggest that CHEK1 inhibition may disrupt mitochondrial proteostasis through a mechanism independent of the drug’s intended catalytic target.

The third model, PRKCA, demonstrated how inhibitor-induced structural changes can redirect a kinase within the cell. Upon Gö 6983 binding, proximity labeling revealed a rapid shift of PRKCA toward membrane-associated proteins at cell junctions, including tight junction, adherens junction, and desmosome components, as well as the known interactor integrin beta-1. Calcium imaging ruled out changes in intracellular calcium as the driver, and a dose-response experiment showed that these junctional proximity changes occurred at significantly lower drug concentrations than other effects, consistent with a specific on-target mechanism. Catalytically inactive and constitutively active PRKCA mutants responded identically, confirming the phenotype is independent of catalytic inhibition. Live-cell imaging of EGFP-tagged PRKCA captured the kinase relocating to the cell periphery—particularly cell-cell contact sites—within eight minutes of drug addition. The researchers propose that Gö 6983 binding opens the C2 domain, exposing a lysine cluster that can bind the junctional lipid PIP2, thereby recruiting the inhibited kinase to membranes through a calcium-independent route.

Taken together, the study establishes the ATP-binding site as a major organizing center of kinase conformation and interaction, and suggests that inhibitor-induced non-catalytic gain-of-function is likely far more prevalent among kinases with autoinhibitory domains than currently appreciated. The authors point to existing examples such as the JAK2 inhibitor ruxolitinib, which paradoxically primes JAK2 hyperphosphorylation and contributes to side effects after drug withdrawal, and BRAF inhibitors that allosterically promote RAF dimerization and MAPK activation, as evidence that such mechanisms already matter clinically. Because many AID-mediated effects would be missed by conventional target engagement assays focused on catalytic kinetics, the authors advocate for systematic multimodal proteomic profiling of both wild-type and disease-mutant kinases during early drug development. The combination of structural and contextual proteomics is not restricted to kinases and could extend to targets lacking catalytic activity altogether. By mapping inhibitor-modulated conformational and interactome landscapes early, researchers hope to detect unexpected liabilities before they surface in the clinic, ultimately guiding the design of safer and more effective kinase-targeted therapeutics.

Subject of Research: Inhibitor-induced displacement of kinase autoinhibitory domains driving non-catalytic drug effects

Article Title: Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains

Article References: Reber, V., Keller, S., Loosli, S. A., Arima, Y., Kleele, T., Picotti, P., & Gstaiger, M. (2026). Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains. Molecular Systems Biology, 22(9), 1474-1500. https://doi.org/10.1038/s44320-026-00229-2

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00229-2

Keywords: kinase inhibitors, autoinhibitory domains, proteomics, protein-protein interactions, CAMKK2, CHEK1, PRKCA, AMPK, mitochondrial fragmentation, drug mechanisms, conformational change, Molecular Systems Biology